Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for preventive treatment of migraine in adults with major depressive disorder
2019-001989-15Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fremanezumab in migraine and major depressive disorder (MDD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean change in monthly average number of migraine days. Started Oct 2019; status: completed.
02
Drugs
fremanezumab
03
Conditions
migrainemajor depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-001989-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001989-15.